Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
749.92
-3.49 (-0.46%)
Official Closing Price
Updated: 7:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
November 21, 2024
LLY stock struggles, falling 16.85% over the last month due to bearish technicals and political uncertainty. But with projected sales and earnings growth, could this be a buying opportunity?
Via
Benzinga
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
November 21, 2024
Shares of Lilly are cratering, but investors may be surprised to learn what's influencing the volatility.
Via
The Motley Fool
Are Diet Drug Companies Over The Hump?
November 20, 2024
Eli Lilly made a reversal bottom low on Monday after a gap lower. Today’s price action was confirmation.
Via
Talk Markets
Topics
Stocks / Equities
Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate
November 20, 2024
Eli Lilly and Verge Genomics advance ALS drug development with validated targets and a Phase 1B study, part of their $694 million collaboration since 2021.
Via
Benzinga
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
November 20, 2024
PBMs Express Scripts, Caremark, and Optum challenge the FTC's administrative proceedings, arguing it violates constitutional rights and threatens the stability of drug pricing.
Via
Benzinga
Is It Time to Sell Eli Lilly and Pfizer Stocks?
November 20, 2024
Via
The Motley Fool
Eli Lilly Unusual Options Activity
November 19, 2024
Via
Benzinga
LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs
November 20, 2024
Verge Genomics and Eli Lilly have made significant progress in their collaboration to develop ALS treatments, identifying two promising drug targets using AI technology.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
November 20, 2024
From
Verge Genomics
Via
GlobeNewswire
Top Research Reports For Eli Lilly, PepsiCo & Morgan Stanley
November 19, 2024
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., PepsiCo, Inc., and Morgan Stanley.
Via
Talk Markets
What To Do After The Worst Week For Healthcare Stocks Since March 2020?
November 19, 2024
The market was quiet today but we should still expect some gains through year -end albeit a bit choppy.
Via
Talk Markets
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?
November 19, 2024
Eli Lilly & Co. shares plunge 12.5% this month, worst since 2009, due to disappointing earnings and lowered guidance. The future remains uncertain.
Via
Benzinga
Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%
November 19, 2024
Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with favorable safety data.
Via
Benzinga
Jim Cramer: Coinbase Is A 'Winner,' Suggests Buying This 'Hated' Big Pharma Stock
November 19, 2024
Jim Cramer recommends buying hated stock Eli Lilly, while also praising Coinbase and IES Holdings. Marvell and Apple are also solid bets.
Via
Benzinga
The Smartest Megacap Growth ETF to Buy With $500 Right Now
November 19, 2024
Via
The Motley Fool
Topics
ETFs
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
November 18, 2024
Eli Lilly's Phase 3 SUMMIT trial results show tirzepatide's potential to reduce heart failure risk and improve symptoms in obese adults with HFpEF.
Via
Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
November 18, 2024
Via
The Motley Fool
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now
November 17, 2024
Via
The Motley Fool
Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth
November 17, 2024
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 weight-loss drugs like Ozempic.
Via
Benzinga
Topics
Economy
Exposures
Economy
Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Years From Now
November 17, 2024
These stocks have realistic paths to grow larger than Tesla.
Via
The Motley Fool
Not-So-Big Pharma
November 16, 2024
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration.
Via
Talk Markets
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
November 16, 2024
Mergers and acquisitions could make a comeback with Trump headed back to Washington.
Via
The Motley Fool
Topics
Government
Exposures
Political
AskSlim Market Week - Friday, Nov. 15
November 15, 2024
An analysis and commentary on the financial markets.
Via
Talk Markets
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
November 15, 2024
To gain an edge, this is what you need to know today.
Via
Benzinga
Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program
November 15, 2024
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
November 15, 2024
Via
The Motley Fool
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
November 14, 2024
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
Via
Benzinga
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
November 14, 2024
Stocks in these "safe" sectors are selling off as investors gravitate toward growth.
Via
The Motley Fool
Topics
ETFs
Stocks
Exposures
US Equities
2 Top Growth Stocks to Buy on the Dip
November 14, 2024
Their recent issues are nothing to fret over for investors focused on the long game.
Via
The Motley Fool
3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years
November 14, 2024
These are income stocks you can buy and hold forever.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.